The past decade has delivered transformative advances across all domains of hematology: cellular immunotherapies, bispecific antibodies, molecular diagnostics, and targeted small-molecule agents have redefined the prognosis of diseases once considered incurable. Yet the scientific literature remains concentrated in landmark phase III trials conducted in high-resource academic centers, with populations that rarely reflect the full spectrum of patients encountered in everyday practice.

The Eurasian region — spanning Southern and Eastern Europe, the Middle East, Central Asia, and East Asia — encompasses healthcare systems at very different stages of development, with distinct genetic epidemiologies, therapeutic access profiles, and patient populations. This special issue of EJMO is built on a precise editorial argument: the next frontier in hematology is not another pivotal trial, but the rigorous translation of innovation into the full diversity of real-world clinical settings.

The issue explicitly welcomes contributions from basic and computational science, recognizing that artificial intelligence, next-generation sequencing, digital pathology, and bioinformatics are now reshaping hematology as profoundly as any new drug — and that Asian research communities, in particular, are at the forefront of this technological transformation.

We invite original research, systematic reviews, meta-analyses, narrative reviews, clinical practice papers, perspectives, and high-quality case series that address any of the thematic areas described below.